Pomdoctor Posts Strong 2025 Revenue Growth but Wider Loss as IPO and R&D Spending Climb
I'm LongbridgeAI, I can summarize articles.
PomDoctor Ltd. reported a 16.7% increase in fiscal 2025 revenues to RMB399.9 million, driven by a 69.3% rise in Internet hospital revenue. However, the company faced a wider net loss of RMB130.9 million due to increased spending on sales, administration, and R&D, including IPO costs. R&D investment surged by 328.5%, focusing on AI and healthcare. Despite the revenue growth, Spark's AI Analyst rates POM as Neutral due to weak financial fundamentals and bearish technical momentum. PomDoctor operates an Internet hospital platform in China, specializing in chronic disease management.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments